Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial.

ABSTRACT:

Background

Metastatic breast cancer (mBC) remains incurable, highlighting the importance of patient-reported outcomes (PROs) in treatment decision making. In the randomized phase III PALOMA-2 trial, health-related quality of life (HRQoL) was maintained in patients receiving first-line palbociclib plus letrozole compared with placebo plus letrozole after a median follow-up of 22.3 months. However, little is known about HRQoL for patients taking palbociclib for an extended period of time. Here, we report the PRO results from the PALOMA-2 trial after a median follow-up time of 90 months.

Patients and methods

Women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) mBC were randomly assigned 2 : 1 to receive palbociclib plus letrozole (

SUBMITTER: Harbeck N 

PROVIDER: S-EPMC11964640 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature